Business Wire

Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia


Regulatory News:

Valbiotis (FR0013254851 - ALVAL, PEA-SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the positive results of its clinical study on the bioavailability and mode of action of TOTUM•070 against hypercholesterolemia.

This innovative protocol, involving 10 healthy volunteers, has first confirmed the presence of 22 metabolites2 of interest in the serum3 of volunteers. The analyses were conducted following oral administration of the clinical dose of 5g of TOTUM•070, used also in the Phase II HEART study. Most of the 22 metabolites are already known for their activity on metabolism. Mode of action analyses then demonstrated, among other things, two effects of TOTUM•070 on human liver cells: inhibition of the cholesterol synthesis pathway and inhibition of cholesterol storage in hepatocytes. These two effects on cholesterol in the liver, which is one of the main metabolic organs, speak in favor of TOTUM•070’s potential against hypercholesterolemia. Following on from these positive results, Valbiotis will announce the outcome of its Phase II HEART clinical efficacy study in the second quarter of 2022, as planned. Its primary endpoint is the reduction of blood LDL-cholesterol.

Pascal SIRVENT, Director of Discovery and Preclinical and Translational Research and Member of the Board of Directors, states: “For the first time, this clinical study has evaluated the bioavailability and hepatic mode of actionof TOTUM•070 in humans. The results live up to our expectations: we can confirm that TOTUM•070 contains many metabolites of interest for regulating cholesterol. Most importantly, the results show that these metabolites are bioavailable in humans and have two significant effects on the regulation of cholesterol in the cells of the human liver, one of the main metabolic organs. These novel clinical data build on the positive preclinical results presented in 2021 and pave the way for further mode-of-action investigations in the liver. Above all, they confirm the potential of TOTUM•070 against hypercholesterolemia in humans, pending the imminent results of our Phase II clinical efficacy study.”

Murielle CAZAUBIEL, Director of Medical, Regulatory and Industrial Affairs and Member of the Board of Directors, adds: “During this clinical study on TOTUM•070, we used an innovative methodology adapted to our plant-based active substances that combines metabolomics and mode of action, which is now producing results. This is a positive clinical development and a very encouraging sign while we wait for the Phase II HEART clinical efficacy results, which will become available in the second quarter of 2022.”

Results of the clinical study on bioavailability and mode of action

This study was conducted on 10 healthy volunteers in an open-label setting and followed a protocol combining metabolomics and mode of action, designed and implemented by Clinic’n’Cell. Professor Gisèle PICKERING, coordinator of the Clinical Investigation Center of the Clermont-Ferrand University Hospital, was Principal Investigator4.

Metabolomic analysis consists of characterizing the metabolites of an active substance in serum, i.e., the molecules derived from this active substance following their intestinal absorption and passage into the blood. After a single oral dose of 5g of TOTUM•070, which is the clinical daily dose, used also in the HEART clinical study (see below), analysis of the volunteers’ serum confirmed the presence of 22 metabolites of interest, the majority of which are known to have a biological activity on metabolism. Kinetic measurements validated good bioavailability of these metabolites in serum within three hours of oral TOTUM•070 intake.

In a second step, the serum collected from volunteers after oral intake of 5g of TOTUM•070 – a serum rich in active metabolites from TOTUM•070 – was used to conduct in vitro tests on human liver cells exposed to massive lipid intake. In this context of “lipotoxic stress”, the volunteers’ serum exerted two major effects on these human liver cell lines: inhibition of the de novo cholesterol synthesis pathway1 and inhibition of cholesterol storage. It also showed no toxicity.

All analyses were conducted with a double control: cell cultures with and without lipotoxic stress, then with and without serum enriched in active metabolites.

Upcoming publication of the Phase II clinical results of TOTUM•070 on hypercholesterolemia

The Phase II HEART clinical trial results will be announced in the second quarter of 2022. This multi-center study will evaluate the efficacy of TOTUM•070 in reducing blood LDL-cholesterol levels versus placebo, in 120 volunteers with mild to moderate untreated hypercholesterolemia. These results will be decisive for the marketing of TOTUM•070, an innovative 100% plant-based active substance containing neither phytosterols nor red yeast rice, and for its positioning as a reference non-drug option against LDL-cholesterol.

About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit:

Name: Valbiotis
ISIN Code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.

1Cholesterol can be brought by food or produced by the body itself ("de novo synthesis").
2Molecules derived from TOTUM•070, following their intestinal absorption and passage into the blood.
3The fraction of blood remaining after all blood cells (red blood cells, leukocytes, platelets) and fibrinogen (a protein involved in clotting) have been removed.
4ID-RCB: 2021-A01211-40

To view this piece of content from, please give your consent at the top of this page.

Contact information

Corporate communication / Valbiotis
+33 5 46 28 62 58

Medias relations / PrPa
+33 6 80 28 47 70

Financial communication / Actifin
Stéphane RUIZ
+33 1 56 88 11 14

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Innovative AI software for the detection of pancreatic diseases: first-in-human application successful16.5.2022 14:21:00 CEST | Press release

Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose. Early detection is crucial for the patient's chance of survival. In Europe today, more than 90 percent of patients die of pancreatic cancer within the first five years after diagnosis. The Medi-Globe Group, a leading international MedTech company based in Achenmühle, Bavaria, will, in cooperation with the French Institut Hospitalo-Universitaire (IHU) Strasbourg, develop the world's first AI software for the detection of diseases of the pancreas in endoscopic ultrasound (EUS) examination. The key technology here is artificial intelligence. As part of large-scale clinical studies prior to market introduction, the AI ​​software has now gone into clinical test with patients, so-called first-in-human applications. This press release features multimedia. View the full release here: The new AI software has the potential to revolutionize t

Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences16.5.2022 14:00:00 CEST | Press release

Apollo (NYSE: APO) and Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a long-term strategic and financial partnership. Under the agreement, Apollo will take a minority equity interest in Sofinnova and commit up to €1 billion of managed capital to its investment funds. This strategic partnership is poised to significantly accelerate Sofinnova’s growth. For Apollo, the investment will meaningfully increase its presence in life sciences and contribute to its growth ecosystem of partners that bring specialized knowledge and networks to its integrated platform. This press release features multimedia. View the full release here: Together, Sofinnova and Apollo will offer entrepreneurs a more comprehensive range of capital solutions to help bring new therapeutic and biotechnology-based solutions to the market. The commitment to invest up to €1 bi

KAUST Spins-in Five Cutting-Edge International Startups and Brings New Tech to Saudi Arabia16.5.2022 13:42:00 CEST | Press release

King Abdullah University of Science and Technology (KAUST) has recently wrapped up 'Destination Deep Tech,' a Saudi-first program that spins in leading-edge global startups to the Kingdom to develop deep tech innovations. The international startups - CeEntek, Hopu, Insignes-Labs, Pasqal, and Proteinea - were chosen to experience the three-month program as a result of their highly advanced technology expansion into the MENA region. This press release features multimedia. View the full release here: The founders of the 5 international startups CeEntek, Hopu, Insignes-Labs, Pasqal, and Proteinea at KAUST (Photo: AETOSWire) “KAUST is the Deep Tech Heart of the Saudi Economy, and so we are delighted to welcome these talented international startups to KAUST and the Kingdom as part of Destination Deep Tech,” said Dr. Kevin Cullen, Vice President of KAUST Innovation. Pasqal, from France, is a leading European Quantum Computing startup t

QCT Delivers on the 5G Promise with Innovative Edge Infrastructures and 5G Solutions16.5.2022 13:00:00 CEST | Press release

Quanta Cloud Technology (QCT), a leading data center hardware solution provider, today announced details around its participation at the Big 5G Event 2022, being held onsite from May 16 – May 18, at the Austin Convention Center in Austin, Texas. QCT will showcase 5G infrastructure and solution demos at Booth #300 for both public and private networks and share their latest insights at the event. This press release features multimedia. View the full release here: (Graphic: Business Wire) To support the ever-growing compute and networking needs at the telco edge, QCT showcases its latest QuantaEdge products and solutions powered by Intel Xeon-SP and Xeon-D processors, spanning carrier grade 5G systems, edge servers and radio units that are cloud native to deliver maximum deployment flexibility. QCT demo highlights include: QuantaEdge EGD33B-WT - a next-gen outdoor pole-mount edge server designed for vRAN/MEC use cases, featuring a

Solynta and Incotec Announce Partnership to Optimize Performance of Hybrid True Potato Seeds16.5.2022 12:00:00 CEST | Press release

Hybrid potato innovator Solynta and seed enhancement company Incotec have entered in a collaboration agreement. By combining forces, the group will bring world-class seed technology and elite genetics to potato farmers worldwide. Solynta is a Netherlands-based company using hybrid potato breeding to grow a more sustainable future. Solynta has developed a unique portfolio of hybrid potato varieties for farmers that are dependable, productive and resilient to climate change. Incotec, a global seed enhancement company, has developed technologies including a new pelletization method and seed priming formula specifically tailored for true potato seeds. This seed technology will allow Solynta’s true potato seeds to succeed in diverse growing environments. Johan Trouw, Solynta Supply Chain Director and co-founder, noted, “At Solynta, we believe that partnering with industry leaders like Incotec supports our mission of creating solutions for food and nutritional insecurity. Their expertise in